What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
Patient developed atrial fibrillation on Ibrutinib, severe fatigue and intolerance to Zanubrutinib and a maculopapular rash (grade 2) on Acalabrutinib
Community PollStarted
In patients with CLL who have intolerance to multiple covalent BTK inhibitors, what is your next step in management?
25 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on
This is a great question, and the answer is that I probably would not rechallenge with a BTK inhibitor. Many patients who develop an intolerance to a BTKi can remain on the drug with supportive care for the toxicity and/or dose reduction, which is not always effective. If someone truly had an intole...
Join for free or sign in to see the full answer